Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12ETN | ISIN: CA98420N1050 | Ticker-Symbol: XP0
Tradegate
04.06.25 | 17:19
27,000 Euro
+0,75 % +0,200
1-Jahres-Chart
XENON PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
XENON PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
26,60026,80012:00
26,60027,00010:54

Aktuelle News zur XENON PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrXenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)65VANCOUVER, British Columbia and BOSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing...
► Artikel lesen
12.05.Xenon Pharmaceuticals Inc. - 10-Q, Quarterly Report1
12.05.Xenon Pharmaceuticals Inc. - 8-K, Current Report1
12.05.Xenon Pharmaceuticals Inc.: Xenon Reports First Quarter 2025 Financial Results and Provides Business Update192- Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 - Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD...
► Artikel lesen
09.05.What to Expect from Xenon Pharmaceuticals' Earnings3
XENON PHARMACEUTICALS Aktie jetzt für 0€ handeln
07.05.Chardan sets XENE stock Buy rating, $55 target on CNS potential1
05.05.Xenon Pharmaceuticals Inc.: Xenon to Report Q1 2025 Financial Results on May 12, 20251
02.05.Xenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)119VANCOUVER, British Columbia and BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing...
► Artikel lesen
04.04.Xenon Pharmaceuticals Inc.: Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 20251
17.03.Xenon Pharmaceuticals Inc. - 8-K, Current Report4
12.03.Xenon Pharmaceuticals Inc.: Xenon to Present at Stifel 2025 Virtual CNS Forum1
05.03.Xenon Pharmaceuticals Inc. - 8-K, Current Report1
27.02.Xenon Pharmaceuticals Inc. - S-8, Securities to be offered to employees in employee benefit plans-
27.02.Xenon Pharmaceuticals Inc.: Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update216- Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch - First of three planned Phase 3 azetukalner MDD studies...
► Artikel lesen
27.02.Xenon Pharmaceuticals Inc. - 10-K, Annual Report-
20.02.Xenon Pharmaceuticals Inc.: Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 20251
17.01.Xenon Pharmaceuticals Inc. - 8-K, Current Report5
13.01.Xenon Pharmaceuticals Inc.: Xenon Outlines Key Corporate Milestone Opportunities for 2025154- Topline data from the first Phase 3 FOS study anticipated in H2 2025 representing major milestone in support of NDA filing and potential launch of azetukalner - First of three planned Phase 3 MDD...
► Artikel lesen
06.12.24Xenon Pharmaceuticals Inc.: Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024227- OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner...
► Artikel lesen
12.11.24Xenon Pharmaceuticals Inc.: Xenon Reports Q3 2024 Financial Results and Business Update267- Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025 - Long-term azetukalner results from X-TOLE open-label extension study in FOS to be presented at AES - Phase...
► Artikel lesen
Seite:  Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1